Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMS 2022 | Immune dysregulation in myeloma and impact on disease progression

David Avigan • 26 Aug 2022
IMS 2022
Multiple Myeloma

David Avigan, MD, Harvard Medical School, Boston, MA, briefly discusses the importance of investigating immune dysregulation in patients with multiple myeloma, highlighting the role of T-cell exhaustion and how this may impact disease progression. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

More from David Avigan

Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
2:26
Impact of dendritic cell fusion vaccine on the microenvironment and outcomes in multiple myeloma
David Avigan • 26 Aug 2022
The role of vaccines in AML
1:26
The role of vaccines in AML
David Avigan • 26 Aug 2022
Vaccines and immunotherapy in hematological malignancies
3:31
Vaccines and immunotherapy in hematological malignancies
David Avigan • 8 Sep 2020
CAR-T: hurdles and ladders
16:02
CAR-T: hurdles and ladders
David Avigan • 13 Sep 2019

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
David Avigan • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
David Avigan • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
David Avigan • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
David Avigan • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals